| 2.54 -0.02 (-0.78%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.14 |
1-year : | 3.67 |
| Resists | First : | 2.69 |
Second : | 3.14 |
| Pivot price | 2.31 |
|||
| Supports | First : | 2.32 |
Second : | 2.08 |
| MAs | MA(5) : | 2.39 |
MA(20) : | 2.32 |
| MA(100) : | 2.52 |
MA(250) : | 2.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 56.3 |
| RSI | RSI(14): 56.1  |
|||
| 52-week | High : | 3.1 | Low : | 1.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OVID ] has closed below upper band by 10.0%. Bollinger Bands are 21.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.7 - 2.71 | 2.71 - 2.72 |
| Low: | 2.41 - 2.42 | 2.42 - 2.43 |
| Close: | 2.52 - 2.54 | 2.54 - 2.56 |
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Thu, 03 Sep 2026
Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Tue, 18 Aug 2026
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Thu, 13 Aug 2026
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - GlobeNewswire
Tue, 07 Jul 2026
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha
Wed, 01 Jul 2026
LEADERS Jeremy Levin, Co-Founder and Executive Chairman, Ovid Therapeutics Inc. - LEADERS Magazine
Fri, 26 Jun 2026
OVID Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 1.6339e+008 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 20,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.797e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 100.6 % |
| Return on Equity (ttm) | -23.5 % |
| Qtrly Rev. Growth | 1.58e+006 % |
| Gross Profit (p.s.) | -383.92 |
| Sales Per Share | -112.87 |
| EBITDA (p.s.) | 6.86957e+006 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.51 |
| Dividend | 0 |
| Forward Dividend | 1.895e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|